Key Takeaways

  • Emideltide (DSIP) was the only peptide of seven rejected by the FDA advisory panel.
  • The panel cited lack of subcutaneous safety and efficacy data despite existing intravenous studies.
  • Panelists flagged poor chemical characterization and availability of approved alternatives.
  • FDA's own scientists had recommended against listing all seven peptides; emideltide was the only one reaffirmed with no override.
  • A compounding recommendation requires formal rulemaking to change legal status.

Why did emideltide (DSIP) fail the advisory panel vote?

Emideltide (DSIP) failed because the advisory committee found no human data for the proposed subcutaneous route—all existing studies used intravenous administration. Panel members cited missing safety data, poor chemical definition, naming inconsistencies, and approved alternatives for insomnia, narcolepsy, and opioid withdrawal. The vote ended 6 yes, 7 no, 1 abstention. Emideltide was the only peptide of seven not recommended for compounding (condorresearch.com).

What evidence gaps drove safety concerns?

FDA staff flagged immunogenicity risks, peptide-related impurities, and API characterization issues for emideltide in their briefing materials. They noted agency reviewers couldn't confirm the candidate's identity or purity to USAN/INN standards and found no toxicity studies for the proposed administration route (fda.gov). Committee members echoed those concerns during deliberations (theatlantic.com).

How does this split compare to other peptides reviewed?

The panel backed six of seven peptides considered for the 503A bulks list—including BPC-157, TB-500, MOTS-c, Semax, and Epitalon—despite FDA staff recommending against all of them. Emideltide stood alone when the panel didn't override the agency. That contrast shows the high bar for compounding list inclusion (condorresearch.com).

What's next for emideltide?

PCAC votes are advisory and carry no force of law. Updating the 503A bulks list requires formal rulemaking under 21 CFR 216.23. With emideltide not recommended and its nomination withdrawn, it remains off-limits to compounding pharmacies under current law (condorresearch.com).

FAQ

What is emideltide (DSIP)?

Emideltide, also called DSIP (delta sleep-inducing peptide), is a synthetic nonapeptide first described in 1977 and not approved by FDA for any indication.

Why did the FDA advisory panel reject emideltide (DSIP) for compounding?

The nomination proposed subcutaneous use while all human data involved intravenous administration. The panel found safety gaps, poor chemical characterization, and existing approved treatments.

Can pharmacies currently compound emideltide (DSIP)?

No. The advisory vote rejected adding it to the 503A bulks list, and without formal rulemaking it remains unlawful to compound.

Did FDA staff support emideltide (DSIP)?

No. FDA scientific reviewers recommended against listing all seven peptides, including emideltide, and the panel concurred only on that one.

Does this decision apply to other countries?

No. The vote affects only the U.S. compounding framework; it does not alter legal status in EU, UK, or research-use-only supply channels.

This article is for general information and is not medical advice. Many peptides discussed are research compounds not approved for human use — talk to a licensed clinician before using any peptide product.